Maxim Group Upgrades Agile Therapeutics (AGRX) to Buy
Tweet
Share
E-mailGet Alerts AGRX Hot Sheet
Price: $1.51 --0%
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Maxim Group analyst Caroline Palomeque upgraded Agile Therapeutics (NASDAQ: AGRX) from Hold to Buy with a price target of $1.00.
For an analyst ratings summary and ratings history on Agile Therapeutics click here. For more ratings news on Agile Therapeutics click here.
Shares of Agile Therapeutics closed at $0.50 yesterday.
You May Also Be Interested In
- New Street Research Upgrades Micron Technology (MU) to Buy
- CIBC Upgrades PRO REIT (PRV-U:CN) to Outperformer
- Jefferies Upgrades Minerva Neurosciences (NERV) to Buy
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
